SAN FRANCISCO — New York drugmaker Acorda Therapeutics Inc. has tapped Paul Hastings to take on a hedge fund that’s declared war on pharmaceutical patents.

J. Kyle Bass and Dallas-based Hayman Capital Management say that drug firms are using expired or otherwise invalid patents to maintain monopoly pricing of their medicines. Partnering with Erich Spangenberg and patent monetization firm IP Navigation Group LLC, Hayman Capital brought two petitions for inter partes review last month under the name Coalition for Affordable Drugs. Each targeted Acorda Therapeutics and its multiple sclerosis treatment Ampyra.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]